Advancing the state of the art of precision medicine to dramatically improve the lives of people with cancer
Oncologie, Inc., is advancing a new paradigm of precision oncology with an RNA-based approach to identify the dominant biology of cancers, particularly in the solid tumor microenvironment. A deep understanding of how to prospectively identify patients based on their dominant biology has allowed Oncologie to search for and obtain clinical-stage therapies that address these biologies, and further develop them into breakthrough therapies.
RNA-based biomarker
Predictive biomarkers historically worked on single-driver mutations yet only 10% of people with cancer have known driver mutations with available targeted therapies.  Oncologie is advancing a new paradigm of precision oncology with an RNA-based approach that identifies a larger number of genes associated with the dominant biology of the tumor microenvironment (TME) within cancer patients.
Bavituximab
Bavituximab is an investigational monoclonal antibody that blocks activation of immunomodulatory TIM and TAM receptors on immune cells through phosphatidylserine (PS) blockade.
Navicixizumab
Navicixizumab is an investigational bi-specific antibody that inhibits the activity of both vascular endothelial growth factor A (VEGF-A) and delta-like ligand 4 (DLL4), two pathways identified in playing a role in tumor progression.